Skip to content
Bomb Report – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 16, 2026
/C O R R E C T I O N — Eli Lilly and Company/
July 9, 2026
Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
July 9, 2026
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
June 26, 2026
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
June 24, 2026
Lilly declares third-quarter 2026 dividend
June 22, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
June 13, 2026
FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
←
Previous Page
1
2
3
4
Next Page
→